search
Back to results

Cranberry Extract and Urinary Infection Prevention: a Clinical Trial (PACCANN)

Primary Purpose

Urinary Tract Infections

Status
Unknown status
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Cranberry extract
Sponsored by
Laval University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Urinary Tract Infections focused on measuring Cranberry, Proanthocyanidins, Urinary catabolites

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy and sexually active women
  • Aged between 18 to 45 years old
  • Recurrence of 2 UTIs in the past 6 months or 3 in the past year
  • Do not have consumed cranberry juice, polyphenols or antioxidant supplements in the last 2 weeks
  • Internet access

Exclusion Criteria:

  • Women who have personal history of acute or chronic renal failure
  • Women who have personal history of urogenital system anomalies, urogenital tractus surgery or intestinal diseases causing malabsorption (e.g., Crohn and celiac diseases)
  • Women who have personal history of kidney stones, taking anticoagulant medication or have taken anticoagulant medication in the last month
  • Women presenting cranberry allergy or intolerance

Sites / Locations

  • Laval UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Optimal dose

Control dose

Arm Description

One capsule with a proanthocyanidins standardized cranberry extract of 18,5 mg twice a day, i.e. in the morning and at night.

One capsule with a proanthocyanidins standardized cranberry extract of 1 mg twice a day, i.e. in the morning and at night.

Outcomes

Primary Outcome Measures

Mean number of urinary tract infections

Secondary Outcome Measures

Full Information

First Posted
October 8, 2015
Last Updated
September 7, 2016
Sponsor
Laval University
Collaborators
Ministry of Agriculture, Fisheries and Food, Quebec, Nutra Canada
search

1. Study Identification

Unique Protocol Identification Number
NCT02572895
Brief Title
Cranberry Extract and Urinary Infection Prevention: a Clinical Trial
Acronym
PACCANN
Official Title
Recurrent Urinary Tract Infection Prevention With Biologic Cranberry Extract Intake Standardized in Proanthocyanidins: A Double-blind Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2016
Overall Recruitment Status
Unknown status
Study Start Date
August 2015 (undefined)
Primary Completion Date
June 2017 (Anticipated)
Study Completion Date
December 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Laval University
Collaborators
Ministry of Agriculture, Fisheries and Food, Quebec, Nutra Canada

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this clinical trial study is to assess, among young and sexually active women presenting recurrent urinary tract infection (UTIs), efficacy of an optimal dose of cranberry extract quantified and standardized to 37 mg/day of Proanthocyanidins (PACs), compared to a control dose quantified and standardized to 2 mg/day of PACs on mean number of new UTIs during a 6-month follow-up period.
Detailed Description
Cranberry juice, fruit (fresh and dried), functional foods, and cranberry dietary supplements are promoted for prevention of urinary tract infections (UTIs) on the basis of their content of cranberry proanthocyanidins (PACs) with "A-type" interflavan bonds. Several clinical trials have assessed efficacy of cranberry-derived products, essentially with cranberry juices, but discordant results have been found. Lack of compliance but mostly lack of standardization in product concentrations can account for the variability among results. Indeed, most clinical trials do not report quantity of PACs. According to most recent studies, quantification of PACs requiring standardized and reproducible methods should be at least 37 mg/day. It can be hypothesized that efficacy of cranberry extract in UTIs prevention among young women can be strongly increased using optimal dosage (standardized to 37 mg/day of PACs). The purpose of this clinical trial study is to assess, among young and sexually active women presenting recurrent UTIs, efficacy of an optimal dose of cranberry extract quantified and standardized to 37 mg/day of PACs, compared to a control dose quantified and standardized to 2 mg/day of PACs on mean number of new UTIs during a 6-month follow-up period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Tract Infections
Keywords
Cranberry, Proanthocyanidins, Urinary catabolites

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
140 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Optimal dose
Arm Type
Active Comparator
Arm Description
One capsule with a proanthocyanidins standardized cranberry extract of 18,5 mg twice a day, i.e. in the morning and at night.
Arm Title
Control dose
Arm Type
Placebo Comparator
Arm Description
One capsule with a proanthocyanidins standardized cranberry extract of 1 mg twice a day, i.e. in the morning and at night.
Intervention Type
Dietary Supplement
Intervention Name(s)
Cranberry extract
Intervention Description
The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.
Primary Outcome Measure Information:
Title
Mean number of urinary tract infections
Time Frame
Within a 6-month period

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy and sexually active women Aged between 18 to 45 years old Recurrence of 2 UTIs in the past 6 months or 3 in the past year Do not have consumed cranberry juice, polyphenols or antioxidant supplements in the last 2 weeks Internet access Exclusion Criteria: Women who have personal history of acute or chronic renal failure Women who have personal history of urogenital system anomalies, urogenital tractus surgery or intestinal diseases causing malabsorption (e.g., Crohn and celiac diseases) Women who have personal history of kidney stones, taking anticoagulant medication or have taken anticoagulant medication in the last month Women presenting cranberry allergy or intolerance
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vicky Leblanc, Dt.P., Ph.D.
Phone
418-656-2131
Ext
2336
Email
vicky.leblanc.1@ulaval.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Sylvie Dodin, M.Sc., MD.
Phone
418-525-4307
Email
sylvie.dodin@ogy.ulaval.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sylvie Dodin, M.Sc., MD.
Organizational Affiliation
Laval University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Laval University
City
Québec
State/Province
Quebec
ZIP/Postal Code
G1V 0A6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vicky Leblanc, Dt.P., Ph.D.
Phone
418-656-2131
Ext
2336
Email
vicky.leblanc.1@ulaval.ca
First Name & Middle Initial & Last Name & Degree
Sylvie Dodin, M.Sc., MD.
Phone
418-525-4307
Email
sylvie.dodin@ogy.ulaval.ca

12. IPD Sharing Statement

Citations:
PubMed Identifier
33757474
Citation
Babar A, Moore L, Leblanc V, Dudonne S, Desjardins Y, Lemieux S, Bochard V, Guyonnet D, Dodin S. High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial. BMC Urol. 2021 Mar 23;21(1):44. doi: 10.1186/s12894-021-00811-w.
Results Reference
derived
PubMed Identifier
29716563
Citation
Asma B, Vicky L, Stephanie D, Yves D, Amy H, Sylvie D. Standardised high dose versus low dose cranberry Proanthocyanidin extracts for the prevention of recurrent urinary tract infection in healthy women [PACCANN]: a double blind randomised controlled trial protocol. BMC Urol. 2018 May 2;18(1):29. doi: 10.1186/s12894-018-0342-7.
Results Reference
derived

Learn more about this trial

Cranberry Extract and Urinary Infection Prevention: a Clinical Trial

We'll reach out to this number within 24 hrs